Asunaprevir is a medication used to treat chronic hepatitis C virus (HCV) infection. It is a direct-acting antiviral (DAA) drug and acts by inhibiting the HCV NS3/4A protease. Asunaprevir is used in combination with other medications such as peginterferon alfa and ribavirin in adults with genotypes 1, 2, and 3 of HCV infection. It is available in tablets and is taken orally.
Asunaprevir, also known by the brand name Sunvepra in some regions, is an investigational drug that was originally intended for the treatment of hepatitis C. Here's a summary of its key points:
Intended use:
- Asunaprevir was designed to target and inhibit the NS3 protease enzyme of the Hepatitis C virus (HCV), specifically genotypes 1 and 4. This enzyme plays a crucial role in the virus's replication process.
- It was intended to be used in combination with other medications, like pegylated interferon and ribavirin, or in interferon-free regimens with other direct-acting antiviral agents.
Development Status:
- Asunaprevir completed Phase III clinical trials in 2013 and showed promising results, particularly in combination with daclatasvir for genotype 1b.
- However, its commercialization was discontinued in 2017 due to several factors, including the emergence of more effective and well-tolerated treatment options for hepatitis C.
Therefore, asunaprevir is not currently a commercially available medication and is not recommended for use.
It's important to remember that seeking information online should not replace consulting a qualified healthcare professional. If you have any questions or concerns regarding hepatitis C treatment options, it's crucial to speak with your doctor for personalized advice.